|
139
|
327
|
3sl8A |
Crystal structure of the catalytic domain of pde4d2 with compound 10o |
|
114
|
325
|
3shyA |
Crystal structure of the pde5a1 catalytic domain in complex with novel inhibitors |
|
137
|
324
|
2ounA |
Crystal structure of pde10a2 in complex with amp |
|
138
|
325
|
2ouvA |
Crystal structure of pde10a2 mutant of d564n |
|
137
|
324
|
2oupA |
Crystal structure of pde10a |
|
133
|
334
|
5wqaA |
Crystal structure of pde4d catalytic domain complexed with selaginpulvilins k |
|
137
|
326
|
5wh6A |
Crystal structure of pde4d2 in complex with inhibitor (s_zl-n-91) |
|
137
|
326
|
5wh5A |
Crystal structure of the pde4d2 catalytic domain in complex with inhibitor (r)-zl-n-91 |
|
134
|
338
|
5vp1A |
Discovery of clinical candidate n-{(1s)-1-[3-fluoro-4-(trifluoromethoxy)phenyl]-2-methoxyethyl}-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1h)-carboxamide (tak-915), a highly potent, selective, and brain-penetrating phosphodiesterase 2a inhibitor for the treatment of cognitive disorders |
|
135
|
334
|
5vp0A |
Discovery of clinical candidate n-{(1s)-1-[3-fluoro-4-(trifluoromethoxy)phenyl]-2-methoxyethyl}-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1h)-carboxamide (tak-915), a highly potent, selective, and brain-penetrating phosphodiesterase 2a inhibitor for the treatment of cognitive disorders |
|
130
|
314
|
5vydA |
Crystal structure of phosphodiesterase domain of rhopde fusion protein from the choanoflagellate salpingoeca rosetta |
|
132
|
323
|
5uwfC |
Crystal structure of human pde10a in complex with inhibitor 16d |
|
139
|
352
|
5uoyA |
Crystal structure of human pde1b catalytic domain in complex with inhibitor 16j (6-(4-methoxybenzyl)-9-((tetrahydro-2h-pyran-4-yl)methyl)-8,9,10,11-tetrahydropyrido[4',3':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6h)-one) |
|
140
|
352
|
5up0A |
Crystal structure of human pde1b catalytic domain in complex with inhibitor 3 (6-(4-chlorobenzyl)-8,9,10,11-tetrahydrobenzo[4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6h)-one) |
|
138
|
339
|
5u7lA |
Pde2 catalytic domain complexed with inhibitors |
|
132
|
338
|
5u7jA |
Pde2 catalytic domain complexed with inhibitors |
|
140
|
338
|
5u7dA |
Pde2 catalytic domain complexed with inhibitors |
|
132
|
340
|
5u7kA |
Pde2 catalytic domain complexed with inhibitors |
|
135
|
342
|
5tzzA |
Crystal structure of human phosphodiesterase 2a in complex with 1-[(3-bromo-4-fluorophenyl)carbonyl]-3,3-difluoro-5-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}piperidine |
|
136
|
341
|
5u00A |
Crystal structure of human phosphodiesterase 2a in complex with 3,3-difluoro-1-[(4-fluoro-3-iodophenyl)carbonyl]-5-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}piperidine |
|
139
|
341
|
5tzaA |
Crystal structure of human phosphodiesterase 2a with 3-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl-1-[(naphthalene-2-yl)carbonyl]piperidine |
|
138
|
341
|
5tz3A |
Crystal structure of human phosphodiesterase 2a in complex with [1,2,4]triazolo[1,5-a]pyrimidin-7-yl}-n-(naphthalene-2-yl)piperidine-3-carboxamide |
|
135
|
341
|
5tzhA |
Crystal structure of human phosphodiesterase 2a in complex with 3,3-difluoro-1-[(4-fluorophenyl)carbonyl]-5-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}piperidine |
|
132
|
342
|
5tzwA |
Crystal structure of human phosphodiesterase 2a in complex with 1-[(3,4-difluorophenyl)carbonyl]-3,3-difluoro-5-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}piperidine |
|
138
|
343
|
5tzcA |
Crystal structure of human pde2a in complex with (5s)-1-[(3-bromo-4-fluorophenyl)carbonyl]-3,3-difluoro-5-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}piperidine |
|
137
|
342
|
5tzxA |
Crystal structure of human phosphodiesterase 2a in complex with 1-[(3-chloro-4-fluorophenyl)carbonyl]-3,3-difluoro-5-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}piperidine |
|
137
|
329
|
5tkbA |
Crystal structure of human phosphodiesterase 4d in complex with a tetrafluoranline compound |
|
135
|
336
|
5ohjA |
Human phosphodiesterase 4b catalytic domain in complex with a pyrrolidinyl inhibitor. |
|
135
|
333
|
5l8yA |
Crystal structure of t. brucei pde-b1 catalytic domain with inhibitor npd-937 |
|
140
|
330
|
5lboA |
Crystal structure of human phosphodiesterase 4d2 catalytic domain with inhibitor npd-001 |
|
138
|
337
|
5laqA |
Crystal structure of human phosphodiesterase 4b catalytic domain with inhibitor npd-001 |
|
128
|
324
|
5k32A |
Pde4d crystal structure in complex with small molecule inhibitor |
|
134
|
323
|
5jo3B |
Pde5a for nav1.7 |
|
127
|
315
|
5b4kA |
Crystal structure of the catalytic domain of human pde10a complexed with n-(4-((5-methyl-5h-pyrrolo[3,2-d]pyrimidin-4-yl)oxy)phenyl)-1h-benzimidazol-2-amine |
|
129
|
315
|
5axpA |
Crystal structure of the catalytic domain of pde10a complexed with 1-(2-fluoro-4-(2-oxo-1,3-oxazolidin-3-yl)phenyl)-5-methoxy-3-(1-phenyl-1h-pyrazol-5-yl)pyridazin-4(1h)-one |
|
134
|
329
|
5h2qA |
Crystal structure of t brucei phosphodiesterase b2 bound to compound 13e |
|
132
|
315
|
5axqA |
Crystal structure of the catalytic domain of pde10a complexed with highly potent and brain-penetrant pde10a inhibitor with 2-oxindole scaffold |
|
131
|
335
|
5g5vA |
Crystal structure of t. brucei pde-b1 catalytic domain with inhibitor npd-038 |
|
137
|
333
|
5g57A |
Crystal structure of t. brucei pde-b1 catalytic domain with inhibitor npd-001 |
|
135
|
329
|
5h2rA |
Crystal structure of t brucei phosphodiesterase b2 bound to compound 15b |
|
135
|
333
|
5g2bA |
Crystal structure of t. brucei pde-b1 catalytic domain with inhibitor npd-008 |
|
128
|
315
|
5edeB |
Human pde10a in complex with 1-(4-chloro-phenyl)-3-methyl-1h-thieno[2,3-c]pyrazole-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide at 2.2a |
|
123
|
313
|
5ediA |
Human pde10a, 6-chloro-5,8-dimethyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-2h-[1,2,4]triazol-3-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyridine, 2.20a, h3, rfree=23.5% |
|
127
|
313
|
5edgA |
Human pde10a in complex with 3-(2-chloro-5-phenyl-3h-imidazol-4-yl)-1-(3-trifluoromethoxy-phenyl)-1h-pyridazin-4-one at 2.30a |
|
125
|
320
|
5ediB |
Human pde10a, 6-chloro-5,8-dimethyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-2h-[1,2,4]triazol-3-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyridine, 2.20a, h3, rfree=23.5% |
|
125
|
314
|
5edeA |
Human pde10a in complex with 1-(4-chloro-phenyl)-3-methyl-1h-thieno[2,3-c]pyrazole-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide at 2.2a |
|
124
|
315
|
5edgB |
Human pde10a in complex with 3-(2-chloro-5-phenyl-3h-imidazol-4-yl)-1-(3-trifluoromethoxy-phenyl)-1h-pyridazin-4-one at 2.30a |
|
123
|
312
|
5edhA |
Human pde10a, 8-ethyl-5-methyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-c]pyrimidine, 2.03a, h3, rfree=22.7% |
|
125
|
307
|
5dh4A |
Pde10 complexed with 5-chloro-n-[(2,4-dimethylthiazol-5-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine |
|
124
|
323
|
5dh5A |
Pde10 complexed with n-[(1-methylpyrazol-4-yl)methyl]-5-[[(1s,2s)-2-(2-pyridyl)cyclopropyl]methoxy]pyrazolo[1,5-a]pyrimidin-7-amine |
